



UCB's General Meeting of Shareholders 2025

- For financial year 2024: Gross dividend of € 1.39 per share (+ 2%), payable on 29 April 2025
- All agenda items put to vote approved
- UCB's Board of Directors composed by a majority of independent directors
- The message of Jean-Christophe Tellier, CEO of UCB is available on UCB's global corporate website

Brussels (Belgium), 24 April 2025 – 18:00 (CET) (regulated information) – Today, UCB held its Annual General Meeting of Shareholders (AGM). The Company offered the choice to UCB shareholders to either participate in-person or to cast their vote by proxy. At the AGM 155.506.427 shares (81,87% of shares entitled to vote) were present or represented.

The message of Mr. Jean-Christophe Tellier, Chief Executive Officer of UCB, published at the occasion of this general meeting, is available on the UCB [website](#).

During his speech, UCB's CEO Jean-Christophe Tellier commented: *"Over the past year, we have reinforced our mission to create solutions that empower people living with severe diseases to live their best lives, free from the burden of illness. Through our relentless focus on execution, we have achieved significant milestones in 2024... this year and as part of commitment to leaving no patient behind, we are dedicated to advancing the development of our medicines for pediatric populations. We're very pleased with the progress in addressing two high unmet need pediatric indications—psoriasis (PSO) and hidradenitis suppurativa (HS)—with Phase 3 studies started.*

Further commenting on the 2025 performance, Jean-Christophe stated: "2025 is proving to be another year of progress on its growth path thanks to our dedicated employees and unwavering commitment to creating value for patients and society. Our five-growth drivers had a great start in 2025. We are continuing their launches around the globe, reaching more and more patients, and improving access to medicine."

The AGM approved for the financial year 2024 the payment of a gross dividend of € 1.39 per share (net dividend of € 0.973 per share) compared to € 1.36 per share for 2023 (net dividend of € 0.952 per share). The ex-dividend date is 25 April 2025, the dividend (coupon no. 28) will be payable as of 29 April 2025

During the AGM, the mandate of John Peacock as independent director was renewed for a term of 4 years, and he will continue to be the Chair of the Board.

The AGM also acknowledged the departure of Susan Gasser from UCB's Board of Director and Scientific Committee. During his speech, Jean-Christophe Tellier expressed his deepest gratitude in name of UCB and himself to Susan Gasser for her invaluable contributions to UCB's Board and Scientific Committee.

In replacement of Susan Gasser, Fiona Powrie was appointed as independent director. Fiona Powrie's mandate will start on 1 January 2026 and expire at the end of the AGM of 2029. She will be a member of the Scientific Committee.





UCB News

Mr Stefaan Heylen was appointed director, for a term of 4 years, upon proposal of UCB's reference shareholder (Financière de Tubize), in replacement of Fiona du Monceau who joined the Executive Committee on 12 March 2024.

The Board of directors, as well as each of its special committees, continues to be composed of a majority of independent directors. The Board composition will also continue to be compliant with the requirement of the BCCA (Belgian Code of Companies and Associations) that at least one third of the members of the Board must be of a different sex than that of the other members.

For the curriculum vitae of the Board members, please visit the UCB website: <https://www.ucb.com/investors/UCB-governance>.

All other agenda items put to vote at the AGM were approved by the shareholders. More information including details of the votes will be available soon on [UCB's website](#).

The Integrated Annual Report 2024 of UCB can be downloaded on UCB's website at <https://www.ucb.com/investors/Download-center> or is available on the online portal at <https://reports.ucb.com/>.

The financial results for the first half year 2025 will be published on 31 July 2025.

Next year's General Meeting will be held on 30 April 2026.

For further information, contact UCB:

Investor Relations

Antje Witte
Investor Relations, UCB
T +32.2.559.9414
Antje.witte@ucb.com

Global Communications

Laurent Schots
Media Relations, UCB
T+32.2.559.9264
Laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB).



Inspired by **patients**.
Driven by **science**.





Forward looking statement

This document contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document.

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, you are cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB.





UCB News

UCB expressly disclaims any obligation or duty to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

